| URL | https://bioprocessintl.com/bioprocess-insider/faci |
| Source | Bio Process International |
| Date Published | 04/28/2022 |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Genezen |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2022 |
| Domestically, the work will be done: | In-house |
| City reshored to: | Indianapolis |
| State(s) reshored to: | IN |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | gene therapy CDMO |
| What domestic positive factors made reshoring more attractive? | Lead time/Time to market |